Navigation Links
Caraco Pharmaceutical Laboratories, Ltd. Announces Settlement of Ethyol(R) ANDA Patent Litigation
Date:8/2/2009

DETROIT, Aug. 3 /PRNewswire-FirstCall/ -- Caraco Pharmaceutical Laboratories, Ltd. (NYSE Amex: CPD) announces today that it has executed a settlement agreement with MedImmune, stipulating the dismissal of the lawsuits filed in the United States District Court for the District of Maryland regarding the submission of an Abbreviated New Drug Application (ANDA) for a generic version of Ethyol(R).

Under the settlement agreement, MedImmune grants Caraco a license to certain patents, permitting Caraco to continue marketing a generic version of Ethyol(R) in the United States. The settlement resolves the entirety of the litigations between the parties.

The terms of the settlement are confidential.

Detroit-based Caraco Pharmaceutical Laboratories, Ltd., develops, manufactures, markets and distributes generic and private-label pharmaceuticals to the nation's largest wholesalers, distributors, drugstore chains and managed care providers.

Safe Harbor: This news release contains forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Without limitation, the words "believe" or "expect" and similar expressions are intended to identify forward-looking statements. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties are contained in the Corporation's filings with the Securities and Exchange Commission, including Part I, Item 1A of our most recent Form 10-K, and include but are not limited to: information of a preliminary nature that may be subject to adjustment, potentially not obtaining or delay in obtaining FDA approval for new products, governmental restrictions on the sale of certain products, development by competitors of new or superior products or less expensive products or new technology for the production of products, the entry into the market of new competitors, market and customer acceptance and demand for new pharmaceutical products, availability of raw materials, timing and success of product development and launches, dependence on few products generating majority of sales, product liability claims for which the Company may be inadequately insured, and other risks identified in this report and from time to time in our periodic reports and registration statements. These forward-looking statements represent our judgment as of the date of this report. We disclaim, however, any intent or obligation to update our forward-looking statements.


'/>"/>
SOURCE Caraco Pharmaceutical Laboratories, Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Caraco Pharmaceutical Laboratories, Ltd. Announces Change to Executive Team as Jitendra N. Doshi Assumes Position of CEO
2. Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2010
3. Caraco Pharmaceutical Laboratories, Ltd. Announces Filing of Purported Class Action Lawsuits
4. Forest Laboratories and H. Lundbeck A/S Enter Into Settlement Agreement With Sun and Caraco Related to LEXAPRO(R) Patent Litigation
5. Caraco Pharmaceutical Laboratories, Ltd. Enters Into Asset Purchase Agreement with Forest Laboratories, Inc. to Settle Lexapro(R) (escitalopram oxalate) ANDA Patent Litigation
6. Caraco Pharmaceutical Laboratories, Ltd. Announces an Indefinite Reduction in its Workforce
7. Caraco Pharmaceutical Laboratories, Ltd. Updates on Financial Position
8. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Action
9. Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Fiscal Year 2009, Updates on FDA Inspection
10. Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Roxicodone(R) Tablets
11. Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Topamax(R) Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... ... December 05, 2016 , ... ... at the 2016 Anti-Aging & Beauty Awards at The Aesthetic & Anti-aging ... Anti-aging Medicine European Congress (AMEC) brings together the industry’s leading scientific experts, ...
(Date:12/5/2016)... ... 2016 , ... A newly released study has found that ... accuracy of placing precordial electrodes with little cognitive effort and a high degree ... studies have shown that single electrode misplacement is one of the single largest ...
(Date:12/4/2016)... ... December 03, 2016 , ... The Lymphoma Research Foundation (LRF) ... and serving the lymphoma community through a comprehensive series of education programs, outreach ... in New York City, with long-time partners The Paul Foundation, on November 10, ...
(Date:12/4/2016)... ... 03, 2016 , ... While James Earl Jones is known for myriad roles ... show called "Front Page". One of the forthcoming episodes examines mammogram techniques; a very ... in large part due to early detection. Like any other disease, treatments have a ...
(Date:12/4/2016)... ... December 03, 2016 , ... Penrose Senior Care Auditors® was ... Tuesday evening at the 26th Annual SMU Cox Dallas 100™ Awards Ceremony and ... Institute for Entrepreneurship. Dallas 100™, co-founded by the Caruth Institute, honors the ingenuity, ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... , Dec 5, 2016 Research and Markets ... Market - Global Forecast to 2021" report to their offering. ... , , ... reach 17.27 billion by 2021, at a CAGR of 5.3% from 2016 ... growing number of obesity cases, increasing government spending on healthcare, and rising ...
(Date:12/5/2016)... PharmaBoardroom today releases its new 70 page Switzerland Healthcare & Life ... , , ... stakeholders crucial insight into Switzerland ; a country located ... of the world,s most important international health institutions as well as two ... number one ranking globally in terms of ease of doing business and ...
(Date:12/4/2016)... , Dec. 4, 2016 Blueprint ... in discovering and developing targeted kinase medicines for ... from its ongoing Phase 1 trial evaluating BLU-285, ... with advanced systemic mastocytosis (SM). Blueprint Medicines is ... of D816V mutant KIT. Approximately 90 to 95 ...
Breaking Medicine Technology: